Skip to main content

Table 3 Lung function tests.

From: Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function

 

VC

FEV1

FEV1%VC

MEF50

Raw

RV

Cst

DLCO

Sarcoidosis

101 ± 19

96 ± 19

96 ± 10

81 ± 35

77 ± 28

93 ± 20

91 ± 6

102 ± 21

IPF

79 ± 17

83 ± 18

106 ± 10

84 ± 34

83 ± 26

73 ± 22

44 ± 6

59 ± 8

EAA

82 ± 29

80 ± 26

99 ± 15

80 ± 44

102 ± 63

95 ± 35

65 ± 30

78 ± 26

SCL

88 ± 23

84 ± 18

101 ± 11

72 ± 21

89 ± 41

93 ± 28

71 ± 36

65 ± 28

CVD

77 ± 16

78 ± 14

105 ± 14

70 ± 27

85 ± 13

82 ± 23

57 ± 20

68 ± 25

WG

98 ± 22

90 ± 18

99 ± 19

68 ± 25

91 ± 16

111 ± 30

80 ± 22

90 ± 29

PLH

86 ± 14

72 ± 22

85 ± 13

46 ± 25

93 ± 19

105 ± 38

81 ± 18

70 ± 18

Silicosis

77 ± 25

69 ± 26

86 ± 16

52 ± 26

91 ± 26

99 ± 33

74 ± 21

86 ± 21

DIPF

79 ± 20

81 ± 19

103 ± 10

64 ± 20

88 ± 10

82 ± 20

49 ± 21

57 ± 21

COP

90 ± 32

76 ± 30

85 ± 22

44 ± 32

106 ± 16

87 ± 51

64 ± 32

75 ± 26

  1. Data are mean percentages ± SD. VC - vital capacity, FEV1 - forced expiratory volume in 1 sec, MEF50 - maximal expiratory flow at 50% of FVC, Raw - airway resistance, RV - residual volume, CST - static lung compliance, DLCO - diffusing capacity of the lungs for carbon monoxide.